Breaking News

Ligand, ABBA Enter OmniAb Platform Pact

March 28, 2016

Licenses platform to generate fully human mono- and bispecific antibodies

Ligand Pharmaceuticals Inc. has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company developing immuno-oncology therapies, under which ABBA will be able to use the OmniRat, OmniMouse and OmniFlicplatforms to generate fully human mono- and bispecific antibodies. Ligand will receive an initial access payment, and will be eligible to receive clinical milestones and royalties for each successful OmniAb antibody. ABBA will be responsible for all program related costs.

“OmniAb will provide ABBA with industry-leading technology for generation of novel antibody therapeutics to further their therapeutic strategy,” said John Higgins, chief executive officer of Ligand. “This is the third OmniAb license deal since the close of the OMT acquisition and the 19th overall OmniAb Ligand partner, and continues to show the licensing power that the OmniAb franchise brings to Ligand.”
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer